BIOTRONIK US Launches Smallest MR Conditional Quadripolar Cardiac Resynchronization Therapy Pacemaker

Edora HF-T QP Completes BIOTRONIK's ProMRI Portfolio LAKE OSWEGO, Ore., Aug. 21, 2017 -- (Healthcare Sales &Marketing Network) -- BIOTRONIK today announced FDA approval and commercial availability of Edora HF-T QP, an MR conditional quadripolar (QP) c... Devices, Cardiology, FDA, Product Launch BIOTRONIK, Edora HF-T QP, cardiac resynchronization therapy, pacemaker
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 19 March 2019Source: Canadian Journal of CardiologyAuthor(s): Nicolas Bergeron, Valérie Lafrenière-Bessi, Maxime Laflamme, François Philippon, Frédéric JacquesAbstractA 60-year-old man with cardiac resynchronization therapy defibrillator (CRT-D) lead endocarditis underwent transvenous lead extraction complicated by coronary sinus laceration and tamponade. Severe left ventricular dysfunction and unstable hemodynamic parameters persisted after emergent sternotomy, drainage and repair. Reinstitution of cardiac resynchronization therapy with an epicardial de...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
AbstractThe single right ventricle (RV) in hypoplastic left heart syndrome (HLHS) often develops systolic dysfunction with time and this affects prognosis. Mechanical dyssynchrony has been reported in HLHS but has not consistently correlated with systolic function or electrical dyssynchrony. The aims of this study were to assess the relationship between RV mechanical dyssynchrony, RV systolic function, and QRS duration on surface electrocardiography. We hypothesized that surface QRS duration would not be an adequate indicator of mechanical dyssynchrony compared with dyssynchrony parameters. Retrospective analysis of echoca...
Source: Mammalian Genome - Category: Genetics & Stem Cells Source Type: research
Optimal atrioventricular delay (AVD) achieves maximum cardiac output in patients undergoing cardiac resynchronization therapy (CRT). Nonoptimal AVD decreases left ventricular (LV) end-diastolic volume and causes loss of flow momentum prior to LV ejection.
Source: Journal of the American Society of Echocardiography - Category: Cardiology Authors: Source Type: research
Pacing and Clinical Electrophysiology, Volume 0, Issue ja, -Not available-.
Source: Pacing and Clinical Electrophysiology : PACE - Category: Cardiology Authors: Tags: EDITORIAL ‐INVITED Source Type: research
Abstract Stroke is a devastating complication of atrial fibrillation (AF) the odds of which can be reduced by use of oral anticoagulation based on the stroke risk score.1,2 Patients with asymptomatic clinical AF have a similar stroke risk as patients with symptomatic clinical AF.3 Thus far, electrocardiographic- (ECG) or Holter monitor-detected AF is a prerequisite before use of oral anticoagulation,1,2 because the guideline recommendations are based on studies that included only ECG- or Holter-detected AF ('clinical' AF).1,2 In the past decades increasing number of cardiac implantable electronic devices (CIED) ha...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Cardiac resynchronization therapy (CRT) improves quality of life and survival in patients with heart failure, but it has not been rigorously investigated in LVAD patients. Furthermore, the effects of different pacing strategies on hemodynamics in LVAD recipients is unknown.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 91 Source Type: research
We present the full study cohort of the first prospective study evaluating outcomes with right ventricular (RV) vs biventricular (BiV) pacing in LVAD patients.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 90 Source Type: research
Exercise-induced left bundle branch block (LBBB) is rarely observed in exercise testing, and usually implies a worse prognosis. Cardiac resynchronization therapy (CRT) is well validated in patients with heart failure with reduced ejection fraction (HFrEF) and LBBB. Although the indications of CRT do not include exercise-induced LBBB, the functional impairment secondary to dynamic electromechanical dyssynchrony could potentially be improved with CRT.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 71 Source Type: research
Cardiac resynchronization therapy (CRT) has been shown to shorten QRS duration (QRSd) and improve ejection fraction (EF) in adults with congenital heart disease (ACHD) and children with heart failure with reduced ejection fraction (HFrEF). It is not known whether CRT confers a survival benefit. We sought to determine whether CRT is associated with longer transplant-free survival after adjusting for patient factors.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 478 Source Type: research
The FDA has given BIOTRONIK approval to introduce the company’s Acticor and Rivacor lines of high-voltage cardiac rhythm implants. They’re designed to treat tachycardia (likely supraventricular tachycardia (SVT) and have been made to be s...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiology Source Type: blogs
More News: Cardiac Resynchronization Therapy | Cardiology | Heart | Marketing